The Lifestyle Parasite Risk Assessment aligns with the One Health model
CVS Launches Lifestyle Parasite Risk Assessment To Support Risk-based Veterinary Prescribing
1 month ago 
292 views
CVS has announced the launch of a new Lifestyle Parasite Risk Assessment initiative, designed to help its veterinary teams to take a sustainable, risk-based approach to parasite control in companion animals.
The new framework supports clinicians in making informed prescribing decisions and involves the whole team in balancing animal welfare, public health, and environmental sustainability.
Parasiticides are widely used in small animal medicine to prevent and treat infestations of fleas, ticks, and worms. While these treatments are essential for maintaining pet health and managing zoonotic risks, growing evidence suggests that routine and widespread use of parasiticides may be contributing to environmental harm - particularly in aquatic ecosystems.
Recent studies have highlighted the environmental risks associated with parasiticides, particularly compounds like Fipronil and Imidacloprid, which can enter waterways through household wastewater or runoff. These substances are highly toxic to invertebrates and have been linked to biodiversity loss and disruption of freshwater ecosystems.
CVS’ new approach aims to make it easier for veterinary teams to create a tailored strategy based on each pet’s lifestyle, exposure risk, and household context. It’s Lifestyle Parasite Risk Assessment enables clinicians to evaluate individual risk factors and recommend parasite control programmes that are both effective and environmentally responsible.
The Lifestyle Parasite Risk Assessment aligns with the One Health model, recognising the interconnectedness of animal, human, and environmental health. It considers a wide range of factors before recommending treatment, including:
- Pet-specific behaviours such as scavenging, hunting, or eating raw food
- Environmental exposure, including outdoor access and swimming habits
- Household composition, especially the presence of vulnerable individuals
- Travel history, both domestic and international
- Owner compliance and preferred administration methods
This comprehensive evaluation allows veterinary professionals to determine whether treatment is necessary, and if so, which product and frequency are most appropriate.
To support its clinical teams, CVS is launching a dedicated Lifestyle Parasite Risk Assessment training course for all colleagues who interact with parasiticides. The course covers:
- Environmental impacts of parasiticides
- Best practice guidelines from BSAVA and BVA
- Parasite lifecycle education
- Zoonotic risk management
- Practical application in consultations
- Communication strategies for client engagement
- Integration of the tool across life stages and practice settings
By the end of the course, the whole veterinary team will be equipped to explain the benefits of lifestyle-based prescribing, confidently use the assessment tool, and collaborate with their teams to embed the approach into daily practice.
Elizabeth McLennan Green, Companion Animal Clinical Director at CVS Group, said: “Our prescribing colleagues are taking a risk-based approach to parasiticide use. We’re making it easier to provide individualised prescribing that considers animal, human, and environmental health risks.
“This initiative marks a significant step forward in responsible prescribing. It aims to reduce unnecessary use of chemicals, support our clients in making the best decisions for their pets, protect non-target species, and enhance the profession’s role in environmental stewardship.
“We recognise that there are knowledge gaps in parasiticide use and environmental impact. While further research is needed, introducing achievable lifestyle assessments is a meaningful starting point.”
CVS Group operates across small animal, farm animal, equine and laboratories, with over 500 veterinary practices and referral centres in the UK and Australia. CVS has invested £122 million in its sites, facilities, equipment and technology since the start of 2023, in addition to providing industry leading training and support, to give the best possible care to animals.
More from CVS UK Ltd
- New study reveals key prognostic indicators in canine mast cell tumours
- Ernie’s ball trouble: Managing a challenging oesophageal foreign body
- New study reveals need for cultural change and increased safety focus in companion animal veterinary practices
- CVS Group halves the amount of waste going to landfill
- CVS supports innovative PhD to promote responsible prescribing habits in veterinary practice
